Home›Companies›Biotech & Pharma›Anavatos Bio

Anavatos Bio Inc.

Automated protein manufacturing platform for early-stage research and clinical programs.

Updated Nov 10, 2026·Latest SEC filing Jul 20, 2026·Suggest an edit

About Anavatos Bio

Anavatos Bio is a private company based in Seattle, Washington, incorporated in 2025 in Delaware. It has reported $392,500 raised in one offering on Form D since May 2025. Its chief executive is Leah Klein.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 27, 2025May 9, 2025amended Jul 20, 2026$392,500target not set4$98,125Debt, Simple Agreement for Future EquityRule 506(b)Form D/A ↗1 earlier filing

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Anavatos Bio's Form D filed Jul 20, 2026.

Sources

  1. SECAnavatos Bio Inc. Form D, filed May 9, 2025
  2. SECAnavatos Bio Inc. filing history
  3. CompanyWho We Are